Breakthrough in Alzheimer's Diagnosis: Blood Tests Show Promise

Researchers report that new blood tests could enable faster and more accurate Alzheimer's diagnosis. These tests identify disease biomarkers and may be simpler alternatives to invasive procedures like brain scans and spinal taps. However, their adoption faces hurdles including limited data, lack of FDA approval, and insurance coverage issues.

Researchers reported on Sunday that new blood tests could enable doctors to diagnose Alzheimer's disease faster and more accurately, although some methods appear more effective than others.

Currently, diagnosing Alzheimer's involves confirming the presence of beta-amyloid buildup via brain scans or spinal taps, which are either hard-to-access or uncomfortable. Labs have begun offering blood tests capable of detecting Alzheimer's biomarkers, generating excitement but facing adoption challenges due to limited data and lack of FDA approval.

The growing demand for early Alzheimer's diagnosis sees millions in the US and globally afflicted with the disease. Drugs like Leqembi and Kisunla, effective only in early stages, highlight the necessity for timely diagnosis. Blood tests have shown high accuracy, as noted in a study of Swedish patients, and could benefit primary care doctors who encounter more memory complaints. Still, caution is advised until further testing and FDA guidelines are established.